KR20190031592A - 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법 - Google Patents

글리부리드 및 다른 약물의 정맥내 투여를 위한 방법 Download PDF

Info

Publication number
KR20190031592A
KR20190031592A KR1020197007606A KR20197007606A KR20190031592A KR 20190031592 A KR20190031592 A KR 20190031592A KR 1020197007606 A KR1020197007606 A KR 1020197007606A KR 20197007606 A KR20197007606 A KR 20197007606A KR 20190031592 A KR20190031592 A KR 20190031592A
Authority
KR
South Korea
Prior art keywords
glyburide
drug
hours
administration
continuous infusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197007606A
Other languages
English (en)
Korean (ko)
Inventor
스벤 마틴 자콥슨
Original Assignee
바이오젠 체사피크 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오젠 체사피크 엘엘씨 filed Critical 바이오젠 체사피크 엘엘씨
Publication of KR20190031592A publication Critical patent/KR20190031592A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Anesthesiology (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
KR1020197007606A 2010-07-19 2011-07-18 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법 Ceased KR20190031592A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36568910P 2010-07-19 2010-07-19
US61/365,689 2010-07-19
PCT/US2011/044397 WO2012012347A2 (en) 2010-07-19 2011-07-18 Methods of intravenous administration of glyburide and other drugs

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137004062A Division KR20130133165A (ko) 2010-07-19 2011-07-18 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법

Publications (1)

Publication Number Publication Date
KR20190031592A true KR20190031592A (ko) 2019-03-26

Family

ID=45497399

Family Applications (8)

Application Number Title Priority Date Filing Date
KR1020197007606A Ceased KR20190031592A (ko) 2010-07-19 2011-07-18 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법
KR1020207012483A Ceased KR20200054319A (ko) 2010-07-19 2011-07-18 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법
KR1020187032015A Ceased KR20180123176A (ko) 2010-07-19 2011-07-18 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법
KR1020217042532A Ceased KR20220000943A (ko) 2010-07-19 2011-07-18 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법
KR1020137004062A Ceased KR20130133165A (ko) 2010-07-19 2011-07-18 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법
KR1020257005414A Ceased KR20250026419A (ko) 2010-07-19 2011-07-18 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법
KR1020237040323A Ceased KR20230165363A (ko) 2010-07-19 2011-07-18 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법
KR1020177029156A Active KR101917975B1 (ko) 2010-07-19 2011-07-18 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법

Family Applications After (7)

Application Number Title Priority Date Filing Date
KR1020207012483A Ceased KR20200054319A (ko) 2010-07-19 2011-07-18 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법
KR1020187032015A Ceased KR20180123176A (ko) 2010-07-19 2011-07-18 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법
KR1020217042532A Ceased KR20220000943A (ko) 2010-07-19 2011-07-18 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법
KR1020137004062A Ceased KR20130133165A (ko) 2010-07-19 2011-07-18 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법
KR1020257005414A Ceased KR20250026419A (ko) 2010-07-19 2011-07-18 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법
KR1020237040323A Ceased KR20230165363A (ko) 2010-07-19 2011-07-18 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법
KR1020177029156A Active KR101917975B1 (ko) 2010-07-19 2011-07-18 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법

Country Status (7)

Country Link
US (9) US8946293B2 (https=)
EP (3) EP3586850A1 (https=)
JP (5) JP6188021B2 (https=)
KR (8) KR20190031592A (https=)
CN (2) CN103108637B (https=)
CA (3) CA3101711C (https=)
WO (1) WO2012012347A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481271A (zh) 2009-05-11 2012-05-30 博格生物系统有限责任公司 利用表观代谢转变剂、多维细胞内分子或环境影响剂治疗代谢障碍的方法
KR20190031592A (ko) 2010-07-19 2019-03-26 바이오젠 체사피크 엘엘씨 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법
LT2616064T (lt) 2010-10-21 2019-11-25 Rtu Pharmaceuticals Llc Parengtos naudoti ketorolako kompozicijos
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
WO2013169939A2 (en) 2012-05-08 2013-11-14 Aeromics, Llc New methods
NZ713868A (en) 2013-04-08 2021-12-24 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
KR102370843B1 (ko) * 2013-09-04 2022-03-04 버그 엘엘씨 코엔자임 q10의 연속주입에 의한 암치료 방법
US20160279155A1 (en) 2013-11-06 2016-09-29 Aeromics, Inc. Novel formulations
US10900040B2 (en) 2015-05-29 2021-01-26 University Of Maryland, Baltimore Methods of reducing or preventing intimal damage caused by mechanical stimulation of endothelial cells
WO2017062765A1 (en) * 2015-10-07 2017-04-13 Remedy Pharmaceuticals, Inc. Methods of treating injuries or conditions related to cns edema
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
CN109689037B (zh) 2016-07-29 2022-09-13 生物切萨皮克有限责任公司 利用sur1-trpm4通道抑制剂的医学治疗方法
US11382881B2 (en) 2017-05-05 2022-07-12 Nino Sorgente Methods and compositions for diagnosing and treating glaucoma
WO2018204721A1 (en) 2017-05-05 2018-11-08 Nino Sorgente Methods and compositions for improving eye health
CN108078999B (zh) * 2017-12-22 2020-08-14 沈阳药科大学 用于防治缺血性脑卒中的药物组合物及其制备方法和用途
CN115836050B (zh) 2020-07-17 2024-12-20 上海森辉医药有限公司 磺酰脲类衍生物及其医药用途
US12251388B1 (en) 2024-05-09 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
US12251389B1 (en) 2024-04-22 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856360A (en) * 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
DE10300323A1 (de) * 2003-01-09 2004-10-14 Baxter Healthcare S.A. Sicherheitsbehälter mit erhöhter Bruch und Splitterfestigkeit sowie kontaminationsfreier Außenfläche für biologisch aktive Substanzen und Verfahren zu deren Herstellung
US20080220441A1 (en) * 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
EP2438913B1 (en) 2002-03-20 2020-05-06 University of Maryland, Baltimore A non-selective cation channel in neural cells and compounds that block the channel for use in treating brain swelling
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
US20040073192A1 (en) * 2002-10-15 2004-04-15 Flament-Garcia Mary Jane Intravenous fluid delivery set
US20050148928A1 (en) * 2003-12-31 2005-07-07 Medtronic Minimed, Inc. Multiple layer tubing and method of making same
AU2005245240B2 (en) * 2004-05-20 2010-04-29 Scimar Ltd. Use of drug combinations for treating insulin resistance
EP1802313B1 (en) * 2004-09-18 2010-11-03 University of Maryland, Baltimore Therapeutic agents trageting the ncca-atp channel and methods of use thereof
JP5085326B2 (ja) * 2004-09-18 2012-11-28 ユニバーシティ オブ メリーランド，ボルチモア ＮＣＣａ−ＡＴＰチャネルを標的とする処置剤およびその使用方法
AU2005322136B2 (en) * 2004-12-23 2011-01-06 Hospira, Inc. Port closure system for intravenous fluid container
BRPI0715279A2 (pt) 2006-09-29 2013-06-11 Infa Sa sistema de embalagem, sistema de embalagem para uma composiÇço farmacÊutica, mÉtodo para transferir uma composiÇço farmcÊutica para administraÇço por infusço intravenosa, uso de um sistema de embalagem, kit para administraÇço parenteral de fÁrmacos com um acesso intravenoso e kit admnistraÇço parenteral de princÍpios ativos
CA2691199C (en) * 2007-06-22 2017-09-12 Marc J. Simard Inhibitors of ncca-atp channels for therapy
US20110034560A1 (en) * 2008-01-29 2011-02-10 Sven Jacobson Liquid formulations of compounds active at sulfonylurea receptors
CN101229316B (zh) * 2008-01-31 2010-08-25 广东药学院 一种知母提取物
KR20190031592A (ko) 2010-07-19 2019-03-26 바이오젠 체사피크 엘엘씨 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법

Also Published As

Publication number Publication date
JP6795571B2 (ja) 2020-12-02
JP6188021B2 (ja) 2017-08-30
KR101917975B1 (ko) 2018-11-13
KR20170118960A (ko) 2017-10-25
KR20230165363A (ko) 2023-12-05
US20190328653A1 (en) 2019-10-31
AU2011279878A1 (en) 2013-03-07
US10786445B2 (en) 2020-09-29
WO2012012347A2 (en) 2012-01-26
KR20180123176A (ko) 2018-11-14
JP6506335B2 (ja) 2019-04-24
US8946293B2 (en) 2015-02-03
CN109172363A (zh) 2019-01-11
CA2806069A1 (en) 2012-01-26
CA3225438A1 (en) 2012-01-26
US12226521B2 (en) 2025-02-18
CA3101711A1 (en) 2012-01-26
US11559481B2 (en) 2023-01-24
EP3586850A1 (en) 2020-01-01
US20210154135A1 (en) 2021-05-27
WO2012012347A3 (en) 2012-05-10
JP2016020393A (ja) 2016-02-04
JP2020073595A (ja) 2020-05-14
JP2019038855A (ja) 2019-03-14
US9561176B2 (en) 2017-02-07
US20170333340A1 (en) 2017-11-23
US20130203853A1 (en) 2013-08-08
US20170348227A1 (en) 2017-12-07
KR20220000943A (ko) 2022-01-04
US9254259B2 (en) 2016-02-09
CA3101711C (en) 2024-02-13
KR20200054319A (ko) 2020-05-19
KR20130133165A (ko) 2013-12-06
US20250221924A1 (en) 2025-07-10
KR20250026419A (ko) 2025-02-25
US10052280B2 (en) 2018-08-21
CN103108637A (zh) 2013-05-15
EP2595633A2 (en) 2013-05-29
US20230414489A1 (en) 2023-12-28
US10391053B2 (en) 2019-08-27
EP3339190A1 (en) 2018-06-27
CA2806069C (en) 2021-01-19
CN103108637B (zh) 2018-09-14
US20150157560A1 (en) 2015-06-11
EP2595633A4 (en) 2014-01-22
JP6179574B2 (ja) 2017-08-16
US20160030370A1 (en) 2016-02-04
JP2017105846A (ja) 2017-06-15
JP2013532658A (ja) 2013-08-19

Similar Documents

Publication Publication Date Title
KR101917975B1 (ko) 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법
AU2011279878B2 (en) Methods of intravenous administration of glyburide and other drugs
HK40020325A (en) Methods of intravenous administration of glyburide and other drugs
Class et al. Patent application title: METHODS OF INTRAVENOUS ADMINISTRATION OF GLYBURIDE
HK40002343A (en) Methods of intravenous administration of glyburide and other drugs
HK1185276A (en) Methods of intravenous administration of glyburide and other drugs
HK1185276B (en) Methods of intravenous administration of glyburide and other drugs

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190315

Application number text: 1020137004062

Filing date: 20130219

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190415

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190501

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200115

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190501

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I